Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for liver and metabolic diseases. Founded in 2011, the company has made significant strides in the industry, particularly with its flagship product, resmetirom, which targets non-alcoholic steatohepatitis (NASH) and other liver conditions. Madrigal's commitment to advancing treatment options has positioned it as a key player in the biopharmaceutical sector, with a strong emphasis on research and development. The company’s unique approach to drug development, combined with its robust pipeline, has garnered attention and recognition within the industry. With a focus on improving patient outcomes, Madrigal Pharmaceuticals continues to pave the way for breakthroughs in metabolic health.
DitchCarbon Score
How does Madrigal Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Madrigal Pharmaceuticals's score of 3 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Madrigal Pharmaceuticals's reported carbon emissions
Madrigal Pharmaceuticals, headquartered in the US, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Madrigal Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Madrigal to establish clear climate commitments and emissions reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Madrigal Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
